Association of simple hematological parameters with disease manifestations, activity, and severity in patients with systemic sclerosis

Yayla, Müçteba Enes; İlgen, Ufuk; Okatan, İlyas Ercan; UsluYurteri, Emine; Torğutalp, Murat; Dinçer, Ayşe Bahar Keleşoğlu; Gülöksüz, Emine Gözde Aydemir; Sezer, Serdar; Turgay, Murat; Kınıklı, Gülay; Ateş, Aşkın

doi:10.1007/s10067-019-04685-0

Cited by 26 publications

(29 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NLR elevation is another discriminator for systemic inflammation, which occurs in various cancers [ 13 – 18 ], autoimmune disease [ 28 – 32 ], infection [ 33 , 34 ], and osteoporosis [ 35 ]. Several studies have revealed that an increase in NLR and PLR indicates poor prognosis in many diseases [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical impact of monocyte distribution width and neutrophil-to-lymphocyte ratio for distinguishing COVID-19 and influenza from other upper respiratory tract infections: A pilot study

Lin

Chang

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) has become a pandemic. Rapidly distinguishing COVID-19 from other respiratory infections is a challenge for first-line health care providers. This retrospective study was conducted at the Taipei Medical University Hospital, Taiwan. Patients who visited the outdoor epidemic prevention screening station for respiratory infection from February 19 to April 30, 2020, were evaluated for blood biomarkers to distinguish COVID-19 from other respiratory infections. Monocyte distribution width (MDW) ≥ 20 (odds ratio [OR]: 8.39, p = 0.0110, area under curve [AUC]: 0.703) and neutrophil-to-lymphocyte ratio (NLR) < 3.2 (OR: 4.23, p = 0.0494, AUC: 0.673) could independently distinguish COVID-19 from common upper respiratory tract infections (URIs). Combining MDW ≥ 20 and NLR < 3.2 was more efficient in identifying COVID-19 (AUC: 0.840). Moreover, MDW ≥ 20 and NLR > 5 effectively identified influenza infection (AUC: 0.7055). Thus, MDW and NLR can distinguish COVID-19 from influenza and URIs.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical impact of monocyte distribution width and neutrophil-to-lymphocyte ratio for distinguishing COVID-19 and influenza from other upper respiratory tract infections: A pilot study

Lin

Chang

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Although a well-described side effect of DMF, nausea is generally tolerable with dose titration, dietary modifications, and anti-emetic medications. 15 In addition, many patients were lymphopenic at study entry as has been described, 16 one patient developing severe lymphopenia during the study, requiring study drug discontinuation as a risk factor for progressive multifocal leukoencephalopathy. Although DMF patients showed a small trend toward improvement in their 6MWD, our small sample size did not provide power to suggest efficacy.…”

Section: Discussionmentioning

confidence: 93%

A pilot study of dimethyl fumarate in pulmonary arterial hypertension associated with systemic sclerosis

Kong

Koontz

Morse

et al. 2021

Journal of Scleroderma and Related Disorders

View full text Add to dashboard Cite

Introduction: Given the poor treatment options for pulmonary arterial hypertension–associated systemic sclerosis patients, we sought to determine clinical safety and efficacy of dimethyl fumarate, an Nrf2 agonist, and the effects on biomarkers of oxidative stress on pulmonary arterial hypertension–associated systemic sclerosis in an exploratory interventional clinical trial. Objectives: The primary objectives were to assess the safety and efficacy of treatment with dimethyl fumarate in patients with pulmonary arterial hypertension–associated systemic sclerosis. Methods: This was an investigator-initiated, double-blind, randomized, placebo-controlled trial conducted at two sites in the United States. The primary safety endpoint was the incidence of serious adverse events and all adverse events in dimethyl fumarate compared to placebo-treated patients. The primary efficacy endpoint was the change in 6-min walk distance from baseline to the end of treatment at Week 24 in dimethyl fumarate compared to placebo-treated patients. Results: Six participants were randomized to either placebo (n = 2) or dimethyl fumarate (n = 4). Baseline demographics were similar in both groups. A total of 25 adverse events occurred in 6 subjects, with 14 adverse events (56.0%) having occurred in dimethyl fumarate-treated subjects. Three occurrences were identified as nausea adverse events, and two participants withdrew due to nausea. One participant in the placebo group was withdrawn after a hospitalization serious adverse event due to worsening of heart failure and shortness of breath secondary to anemia. One participant in each group completed protocol. Subjects in the dimethyl fumarate-treated group showed a non-significant reduced decline in 6-min walk distance (relative mean change of −7.07%) from baseline to Week 24 as compared to placebo-treated subjects (relative mean change of −14.97%). Conclusion: Patients treated for pulmonary arterial hypertension–associated systemic sclerosis with 2- and 3-drug regimens, as is now typical for these patients, tolerate dimethyl fumarate poorly. Our small sample size did not provide power to suggest efficacy. We suggest that Nrf2 is still a valid therapeutic target for future trials, using better tolerated Nrf2 agonists.

show abstract

“…The relation between thyroid disorders and abnormalities in haematological parameters by affecting bone marrow is a well-known issue (8). In this context, MPV is one of the determinants of the platelet function which is situated in the routine CBC analysis and was shown to be affected in distinct disease conditions including acute pancreatitis, inflammatory bowel diseases, cardiac disorders, peritonitis, autoimmune disorders and tumoral diseases (10)(11)(12)(13)15,16). The diagnostic role of MPV in thyroid diseases is a novel topic of research with conflicting results.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the hematologic indices in patients with thyrotoxicosis with distinct etiologies: a case-control study

Çetin

Kamış

Karakılıç

et al. 2021

Journal of Health Sciences and Medicine

View full text Add to dashboard Cite

Aim: Thyrotoxicosis is a clinical state of inappropriately high levels of free T4 (thyroxine) and/or free T3 (tri-iodothyronine) in the body caused by distinct etiologies including Graves' disease (GD), subacute thyroiditis (SAT), toxic adenoma and toxic multinodular goiter (TMNG). Simple hematologic indices such as neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and mean platelet volume (MPV) have increasingly been mentioned as measures of presence and severity of thyrotoxicosis. In this study, we aimed to analyze whether there is a link between these peripheral blood parameters and the presence of thyrotoxicosis. Material and Method: A total of 46 GD, 46 TMNG, 39 TA and 45 SAT patients and 45 healthy controls were included. Laboratory parameters and NLR, PLR, and MPV values were recorded from peripheral blood complete blood cell counts for each patient. Results: This study showed that NLR and PLR levels are elevated in patients with SAT in comparison with other thyrotoxic patient groups and controls. The post hoc analysis of comparison of NLR and PLR in each study groups revealed that NLR and PLR were statistically different in the SAT group in comparison to the GD, TMNG, TA, and healthy controls. A significant decrease in the level of MPV was demonstrated in thyrotoxicosis patients (p<0.001). Conclusion: NLR, PLR and MPV that is routinely and automatically calculated from complete blood count plays an important diagnostic role in thyrotoxicosis.

show abstract

Association of simple hematological parameters with disease manifestations, activity, and severity in patients with systemic sclerosis

Cited by 26 publications

References 43 publications

Clinical impact of monocyte distribution width and neutrophil-to-lymphocyte ratio for distinguishing COVID-19 and influenza from other upper respiratory tract infections: A pilot study

Clinical impact of monocyte distribution width and neutrophil-to-lymphocyte ratio for distinguishing COVID-19 and influenza from other upper respiratory tract infections: A pilot study

A pilot study of dimethyl fumarate in pulmonary arterial hypertension associated with systemic sclerosis

Evaluation of the hematologic indices in patients with thyrotoxicosis with distinct etiologies: a case-control study

Contact Info

Product

Resources

About